Abstract
Almost all human cancers have accumulated multiple genetic lesions including oncogenes. It is often unknown whether an oncogene is continuously required for tumorigenesis. Furthermore, it is very difficult to target an essential oncogene with drugs without affecting the corresponding nonmutated protooncogene or related factors. The recent discovery of RNA interference and the application of small interfering RNAs in mammalian cell culture provide now tools to examine the role of oncogenes in tumor development. Furthermore, oncogene-specific siRNAs may become promising candidates for more cancer-specific therapeutic approaches. This review discusses the potential and the limitations of oncogene-targeting siRNAs and describes examples for the application of siRNAs in the functional analysis of oncogenes.
Keywords: rna interference, sirna, shrna, tumorigenesis, cancer, leukemia
Current Pharmaceutical Biotechnology
Title: Oncogene Suppression by Small Interfering RNAs
Volume: 5 Issue: 4
Author(s): Olaf Heidenreich
Affiliation:
Keywords: rna interference, sirna, shrna, tumorigenesis, cancer, leukemia
Abstract: Almost all human cancers have accumulated multiple genetic lesions including oncogenes. It is often unknown whether an oncogene is continuously required for tumorigenesis. Furthermore, it is very difficult to target an essential oncogene with drugs without affecting the corresponding nonmutated protooncogene or related factors. The recent discovery of RNA interference and the application of small interfering RNAs in mammalian cell culture provide now tools to examine the role of oncogenes in tumor development. Furthermore, oncogene-specific siRNAs may become promising candidates for more cancer-specific therapeutic approaches. This review discusses the potential and the limitations of oncogene-targeting siRNAs and describes examples for the application of siRNAs in the functional analysis of oncogenes.
Export Options
About this article
Cite this article as:
Heidenreich Olaf, Oncogene Suppression by Small Interfering RNAs, Current Pharmaceutical Biotechnology 2004; 5 (4) . https://dx.doi.org/10.2174/1389201043376733
DOI https://dx.doi.org/10.2174/1389201043376733 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Transplacental Antioxidants Inhibit Lung Tumors in Mice Exposed to Cigarette Smoke After Birth: A Novel Preventative Strategy?
Current Cancer Drug Targets DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Infectious Co-Factors in HIV-1 Transmission Herpes Simplex Virus Type-2 and HIV-1: New Insights and Interventions
Current HIV Research The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts
Current Women`s Health Reviews The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets A Review on Metal Nanoparticles from Medicinal Plants: Synthesis, Characterization and Applications
Nanoscience & Nanotechnology-Asia Low Utility in Colposcopy-directed Biopsies for Non-high Grade Cytological Abnormalities on PAP Smear
Current Women`s Health Reviews Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy
Current Medicinal Chemistry Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial, In Vitro and In Vivo Antineoplastic Activities, Mechanism of Action, Structural and Thermal Properties of a Small-Novel Pharmaceutical Organometallic Chelate
Mini-Reviews in Medicinal Chemistry